Table 5.

Evaluation of the plasma concentration of Immunoglobulin M (IgM) in mg/dL of 30 participants^# at T0, T1, T2 and T3.

Participants	T0	T1	T2	T3
ALC16	118	103	113	118
AMB03	128	110	130	*
BP26	55	50	42	51
C-A23	95	84	96	*
C-C36	89	91	87	88
CL12	74	94	83	69
CRS33	94	107	111	109
E-S01	106	86	86	100
EEV13	124	133	128	119
FAS05	40	38	42	**
HFS28	155	147	**	**
IMS35	58	55	55	54
J-S42	60	49	60	50
JPF18	109	107	84	80
JSF29	53	53	**	**
LS15	65	67	57	60
LOF29	39	41	42	42
MIV14	60	66	63	60
MPG17	110	103	104	100
NS07	84	80	93	85
NMA30	172	165	158	**
PBL27	116	106	111	**
SVR04	59	62	59	**
TAA10	83	84	76	82
VD10	173	173	176	168
VAR21	156	138	151	168
VAT34	84	85	89	80
VDR32	83	82	67	68
VLA11	64	79	79	72
WN37	73	89	90	*

T0 before treatment (screening); T1 (30 days), T2 (60 days) during treatment, and T3 (90 days) at the end of treatment.

*Participants who did not collected material for immunogenicity analyses at that visit.

**Discontinued participants.

IgM references values for adult individuals, 50 to 300 mg/dL.

^#Mislaid of material collected for immunogenicity analyzes from all visits by one participant.